Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia
Dr Neil Buckholtz , Director of Neuroscience, the National Institute on Aging (NIA), National Institutes of Health (NIH)
The document discusses the formation and goals of the Global Alliance for Genomics and Health. It was started in 2013 to facilitate international sharing of genomic and clinical data. Its goals are to establish common frameworks for data sharing, catalyze specific data sharing projects, and demonstrate the value of aggregating data from many sources. It currently has over 200 partner organizations from 30 countries. Working groups are advancing priorities around regulatory issues, data standards, security, and clinical implementation. The alliance aims to create a growing, sustainable network that continuously improves understanding of human health through large-scale data sharing and analysis.
This document summarizes discussions from the 6th Genomic Medicine Colloquium hosted by the National Human Genome Research Institute. The colloquium brought together 50 international genomic medicine leaders from 25 countries to discuss opportunities for collaboration. Key areas of discussion included establishing standards for genomic data storage, implementing global pharmacogenomic screening programs, developing genomic medicine policy, and creating an international genomic medicine collaborative.
Ethical, Legal, and Social Implications of ELSI Learning Health Systems 2017 Conference, University of Michigan. Learning from the experience and outcomes of every cancer patient
Data sharing drivers in precision oncology, biomedical research, and healthcare. Accelerating discovery, innovation, providing credit for all stakeholders - patients, researchers, care providers, payers.
An analysis of patient diversity in oncology clinical trials found that women and minorities are underrepresented compared to their proportions in cancer incidence rates and the general population. The study analyzed data from 2002-2012 on five cancer types and found that women were underrepresented in lung cancer trials, and that black, Asian/Pacific Islander, and American Indian patients had lower odds of enrollment compared to their white counterparts. The results indicate a need for more inclusive trial recruitment practices to improve generalizability and alleviate health disparities.
Real world data, the National COVID-19 Cohort Consortium, and Oncology 2021Warren Kibbe
The document provides an overview of the National COVID Cohort Collaborative (N3C) presented by Warren Kibbe at a workshop. N3C is a large dataset of de-identified electronic health record data from COVID-19 patients across the United States. It aims to answer clinical research questions through federated analytics while maintaining security and privacy. The dataset contains standardized and harmonized variables from different medical centers and common data models. N3C represents a unique resource for examining the effects of COVID-19 on cancer outcomes and other clinical domains through large-scale analysis of real-world data.
The document discusses precision medicine in cancer and the National Cancer Institute's (NCI) Molecular Analysis for Therapy Choice (NCI MATCH) trial and the Beau Biden Cancer Moonshot initiative. It provides background on cancer statistics and tumor biology. It describes the NCI MATCH trial which matches patients to targeted therapies based on genomic testing of their tumors. It outlines the 30 treatment arms in MATCH. It discusses observations from MATCH so far and notes that precision oncology requires understanding biology, genomics, imaging, and clinical data. It provides an overview of the goals and recommendations of the Beau Biden Cancer Moonshot, including establishing a national cancer data ecosystem to share data.
The document discusses the formation and goals of the Global Alliance for Genomics and Health. It was started in 2013 to facilitate international sharing of genomic and clinical data. Its goals are to establish common frameworks for data sharing, catalyze specific data sharing projects, and demonstrate the value of aggregating data from many sources. It currently has over 200 partner organizations from 30 countries. Working groups are advancing priorities around regulatory issues, data standards, security, and clinical implementation. The alliance aims to create a growing, sustainable network that continuously improves understanding of human health through large-scale data sharing and analysis.
This document summarizes discussions from the 6th Genomic Medicine Colloquium hosted by the National Human Genome Research Institute. The colloquium brought together 50 international genomic medicine leaders from 25 countries to discuss opportunities for collaboration. Key areas of discussion included establishing standards for genomic data storage, implementing global pharmacogenomic screening programs, developing genomic medicine policy, and creating an international genomic medicine collaborative.
Ethical, Legal, and Social Implications of ELSI Learning Health Systems 2017 Conference, University of Michigan. Learning from the experience and outcomes of every cancer patient
Data sharing drivers in precision oncology, biomedical research, and healthcare. Accelerating discovery, innovation, providing credit for all stakeholders - patients, researchers, care providers, payers.
An analysis of patient diversity in oncology clinical trials found that women and minorities are underrepresented compared to their proportions in cancer incidence rates and the general population. The study analyzed data from 2002-2012 on five cancer types and found that women were underrepresented in lung cancer trials, and that black, Asian/Pacific Islander, and American Indian patients had lower odds of enrollment compared to their white counterparts. The results indicate a need for more inclusive trial recruitment practices to improve generalizability and alleviate health disparities.
Real world data, the National COVID-19 Cohort Consortium, and Oncology 2021Warren Kibbe
The document provides an overview of the National COVID Cohort Collaborative (N3C) presented by Warren Kibbe at a workshop. N3C is a large dataset of de-identified electronic health record data from COVID-19 patients across the United States. It aims to answer clinical research questions through federated analytics while maintaining security and privacy. The dataset contains standardized and harmonized variables from different medical centers and common data models. N3C represents a unique resource for examining the effects of COVID-19 on cancer outcomes and other clinical domains through large-scale analysis of real-world data.
The document discusses precision medicine in cancer and the National Cancer Institute's (NCI) Molecular Analysis for Therapy Choice (NCI MATCH) trial and the Beau Biden Cancer Moonshot initiative. It provides background on cancer statistics and tumor biology. It describes the NCI MATCH trial which matches patients to targeted therapies based on genomic testing of their tumors. It outlines the 30 treatment arms in MATCH. It discusses observations from MATCH so far and notes that precision oncology requires understanding biology, genomics, imaging, and clinical data. It provides an overview of the goals and recommendations of the Beau Biden Cancer Moonshot, including establishing a national cancer data ecosystem to share data.
Disease Network is the science that has emerged to diagnose a disease from a network aspect
specifically. Networks are the group that interconnect to each others similarly disease networks are
the one that reveal concelled connection among apparently independent biomedical entities like
physiologic process, signaling receptors, in addition to genetic code, also they prove to exists
intitutive in addition to powerful way to learn/discover or diagnose a disease.Due to these networks,
we can now consume the elderly drugs and its method to learn/discover the new drug
accordingly.Example- Colchicine is used in gout but after repurposing it is also used in mediterranean
fever. This is because there are many factors that affect the body during mediterranean fever and
gout, we know that gout is a form of arthritis that causes pain in joints also mediterranean fever is the
one which is accompanied by pain in joints, therefore colchicine is used as a repurposed drug again.In
repurposing of medicines or drugs we first analyse the change in symptoms and identify the target
organ and accorgingly we produce a drug that is compatible with pharmacokinetics of the body. As
the availablity of transcriptomic,proteomic and metabolomic data sources are increasing day by day it helps in classification of disease .Also there are some networks reffered to as complex networks which can be called as collection of linked junctions/ nodes
This document discusses secondary data analysis and provides examples of large federal health surveys that can be used for secondary analysis, including NHANES and NHIS. It outlines strengths and limitations of secondary data analysis. Complex survey design must be accounted for, including statistical weighting, clustering, and stratification. Several statistical software programs are designed for analyzing complex survey data. The document concludes with a hypothetical case study using NHIS and EPA air pollution exposure data to study the relationship between acrolein levels and childhood asthma episodes.
1. The document discusses issues around privacy and consent related to genomic and medical data sharing. It describes different types of privacy and controversies over sharing the HeLa cell genome without consent.
2. Broad consent for unspecified future uses of data limits informed consent. New models of dynamic and tiered consent that allow individuals more control are discussed.
3. Laws and court cases around privacy and property rights for human tissue are reviewed, including the Moore v. Regents case ruling that discarded bodily tissue is not private property.
The document summarizes Dr. Matthieu-P. Schapranow's presentation at the Festival of Genomics in Boston on turning big medical data into precision medicine. It describes an in-memory database approach that enables real-time analysis of heterogeneous medical data sources. This allows clinicians and researchers to interactively explore patient data, clinical trials, pathways, and literature to obtain personalized treatment recommendations. The system was designed using a human-centered methodology to ensure usability, effectiveness, and feasibility for precision medicine applications.
Future Health Challenges: Developing Global Norms for Data and Results Sharin...ExternalEvents
http://www.fao.org/about/meetings/wgs-on-food-safety-management/en/
Future Health Challenges: Developing Global Norms for Data and Results Sharing during Public Health Emergencies. Presentation from the Technical Meeting on the impact of Whole Genome Sequencing (WGS) on food safety management and GMI-9, 23-25 May 2016, Rome, Italy.
UCSF Informatics Day 2014 - Keith R. Yamamoto, "Precision Medicine"CTSI at UCSF
Keith R. Yamamoto, PhD — Opening Remarks – Precision Medicine
Vice Chancellor for Research
Executive Vice Dean of the School of Medicine
Professor of Cellular and Molecular Pharmacology
UCSF
1) AI systems like Adam and Eve have discovered new scientific knowledge by autonomously generating and testing hypotheses about yeast genes using public databases and laboratory experiments.
2) AI is being applied throughout the drug development process, including target identification, compound design and synthesis, clinical trial optimization, and drug repurposing.
3) Partnerships between pharmaceutical companies and AI firms are exploring applications like generating new immuno-oncology treatments, metabolic disease therapies, and cancer treatments through large-scale data analysis.
Clinical informatics will see more molecular data collected from patients, increased democratization of biomedical data and knowledge, and the integration of data and digital tools to empower patients and support wellness. In the next 10 years, biomedical informatics will focus on predicting and preventing disease before symptoms occur, explaining rare conditions, keeping people healthy longer through personalized care, and ensuring safe, effective, cost-efficient care is delivered to patients.
RADx-UP CDCC presentation for the NIH Disaster Interest GroupWarren Kibbe
Presentation on the RADx-Underserved Populations Coordination and Data Collection Center with an emphasis on how it will help understand and reduce the disparities associated with the COVDI-19 pandemic
Leveraging Text Classification Strategies for Clinical and Public Health Appl...Karin Verspoor
Human-generated text is a critical component of recorded clinical data, yet remains an under-utilised resource in clinical informatics applications due to minimal standards for sharing of unstructured data as well as concerns about patient privacy. Where we can access and analyse clinical text, we find that it provides a hugely valuable resource. In this talk, I will describe two projects where we have used text classification as the basis for addressing a clinical objective: (1) a syndromic surveillance project where the task is the monitoring of health and social media data sources for changes that indicate the onset of disease outbreaks, and (2) the analysis of hospital records to enable retrieval of specific disease cases, for monitoring of the hospital case mix as well as for construction of patient cohorts for clinical research studies. I will end by briefly discussing the huge potential for clinical text analysis to support changing the way modern medicine is practised.
I will discuss the formation and subsequent growth of IRDiRC into an organization with nearly 40 public and private funder members who have collectively pledged over 1 billion euros for rare disease research. I will also present the goals of IRDiRC, the plan that has been developed to achieve them, and the progress that has been made thus far. Finally, I will explore how additional organizations can take part in this international collaborative effort
The International AD Research Funder Consortium (IADRFC) aims to foster collaboration and data sharing between Alzheimer's disease research organizations through developing partnerships, standard templates, and influencing the international research agenda. The Global Alzheimer's Association Interactive Network (GAAIN) is a collaborative effort to provide researchers worldwide access to a vast repository of Alzheimer's research data by establishing a central data infrastructure and engaging data partners. GAAIN will transform heterogeneous local data into a common data model and terminology to allow integrated analysis across datasets.
Developing a national strategy to bring pathogen genomics into practiceExternalEvents
http://www.fao.org/about/meetings/wgs-on-food-safety-management/en/
Developing a national strategy to bring pathogen genomics into practice. Presentation from the Technical Meeting on the impact of Whole Genome Sequencing (WGS) on food safety management and GMI-9, 23-25 May 2016, Rome, Italy.
Healthcare Conference 2013 : Genes, Clouds and Cancer - dr. Andrew LittD3 Consutling
Dell Healthcare provides IT services to healthcare organizations worldwide. They serve over 50% of US hospitals, the top 10 pharmaceutical companies, and 100 insurance organizations. Dell Healthcare manages billions of medical images in the cloud, billions of security events daily, and provides genomic sequencing services. They are sponsoring the first FDA-approved clinical trial using whole genome sequencing to provide personalized cancer treatment to children with neuroblastoma. The trial aims to reduce analysis time from weeks to hours using Dell's high performance computing capabilities and improve collaboration using their genomics cloud. The goal is to expand personalized medicine from treating a few children to hundreds and thousands.
Investigating the Health of Adults: Leveraging Large Data Sets For Your Stud...CTSI at UCSF
Overview of UCSF-CTSI Comparative Effectiveness Large Dataset Analysis Core with emphasis on large, public data sets for studying the health of adults and the care they receive.
The workshop aimed to promote the development and use of atomically precise tools for medical applications. About 50 researchers from diverse fields attended to identify potential collaborations and near-term research projects. The workshop developed several example projects, such as using artificial immune systems or DNA robots to treat diseases. It also identified how precise tools could repair DNA, stem cells, or control blood composition to treat medical issues.
Welcome Remarks and Overview of CTSI ResourcesUCLA CTSI
Welcome Remarks and Overview of CTSI Resources
Steven Dubinett, MD
Director, UCLA Clinical and Translational Science Institute
President/CEO, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Disease Network is the science that has emerged to diagnose a disease from a network aspect
specifically. Networks are the group that interconnect to each others similarly disease networks are
the one that reveal concelled connection among apparently independent biomedical entities like
physiologic process, signaling receptors, in addition to genetic code, also they prove to exists
intitutive in addition to powerful way to learn/discover or diagnose a disease.Due to these networks,
we can now consume the elderly drugs and its method to learn/discover the new drug
accordingly.Example- Colchicine is used in gout but after repurposing it is also used in mediterranean
fever. This is because there are many factors that affect the body during mediterranean fever and
gout, we know that gout is a form of arthritis that causes pain in joints also mediterranean fever is the
one which is accompanied by pain in joints, therefore colchicine is used as a repurposed drug again.In
repurposing of medicines or drugs we first analyse the change in symptoms and identify the target
organ and accorgingly we produce a drug that is compatible with pharmacokinetics of the body. As
the availablity of transcriptomic,proteomic and metabolomic data sources are increasing day by day it helps in classification of disease .Also there are some networks reffered to as complex networks which can be called as collection of linked junctions/ nodes
This document discusses secondary data analysis and provides examples of large federal health surveys that can be used for secondary analysis, including NHANES and NHIS. It outlines strengths and limitations of secondary data analysis. Complex survey design must be accounted for, including statistical weighting, clustering, and stratification. Several statistical software programs are designed for analyzing complex survey data. The document concludes with a hypothetical case study using NHIS and EPA air pollution exposure data to study the relationship between acrolein levels and childhood asthma episodes.
1. The document discusses issues around privacy and consent related to genomic and medical data sharing. It describes different types of privacy and controversies over sharing the HeLa cell genome without consent.
2. Broad consent for unspecified future uses of data limits informed consent. New models of dynamic and tiered consent that allow individuals more control are discussed.
3. Laws and court cases around privacy and property rights for human tissue are reviewed, including the Moore v. Regents case ruling that discarded bodily tissue is not private property.
The document summarizes Dr. Matthieu-P. Schapranow's presentation at the Festival of Genomics in Boston on turning big medical data into precision medicine. It describes an in-memory database approach that enables real-time analysis of heterogeneous medical data sources. This allows clinicians and researchers to interactively explore patient data, clinical trials, pathways, and literature to obtain personalized treatment recommendations. The system was designed using a human-centered methodology to ensure usability, effectiveness, and feasibility for precision medicine applications.
Future Health Challenges: Developing Global Norms for Data and Results Sharin...ExternalEvents
http://www.fao.org/about/meetings/wgs-on-food-safety-management/en/
Future Health Challenges: Developing Global Norms for Data and Results Sharing during Public Health Emergencies. Presentation from the Technical Meeting on the impact of Whole Genome Sequencing (WGS) on food safety management and GMI-9, 23-25 May 2016, Rome, Italy.
UCSF Informatics Day 2014 - Keith R. Yamamoto, "Precision Medicine"CTSI at UCSF
Keith R. Yamamoto, PhD — Opening Remarks – Precision Medicine
Vice Chancellor for Research
Executive Vice Dean of the School of Medicine
Professor of Cellular and Molecular Pharmacology
UCSF
1) AI systems like Adam and Eve have discovered new scientific knowledge by autonomously generating and testing hypotheses about yeast genes using public databases and laboratory experiments.
2) AI is being applied throughout the drug development process, including target identification, compound design and synthesis, clinical trial optimization, and drug repurposing.
3) Partnerships between pharmaceutical companies and AI firms are exploring applications like generating new immuno-oncology treatments, metabolic disease therapies, and cancer treatments through large-scale data analysis.
Clinical informatics will see more molecular data collected from patients, increased democratization of biomedical data and knowledge, and the integration of data and digital tools to empower patients and support wellness. In the next 10 years, biomedical informatics will focus on predicting and preventing disease before symptoms occur, explaining rare conditions, keeping people healthy longer through personalized care, and ensuring safe, effective, cost-efficient care is delivered to patients.
RADx-UP CDCC presentation for the NIH Disaster Interest GroupWarren Kibbe
Presentation on the RADx-Underserved Populations Coordination and Data Collection Center with an emphasis on how it will help understand and reduce the disparities associated with the COVDI-19 pandemic
Leveraging Text Classification Strategies for Clinical and Public Health Appl...Karin Verspoor
Human-generated text is a critical component of recorded clinical data, yet remains an under-utilised resource in clinical informatics applications due to minimal standards for sharing of unstructured data as well as concerns about patient privacy. Where we can access and analyse clinical text, we find that it provides a hugely valuable resource. In this talk, I will describe two projects where we have used text classification as the basis for addressing a clinical objective: (1) a syndromic surveillance project where the task is the monitoring of health and social media data sources for changes that indicate the onset of disease outbreaks, and (2) the analysis of hospital records to enable retrieval of specific disease cases, for monitoring of the hospital case mix as well as for construction of patient cohorts for clinical research studies. I will end by briefly discussing the huge potential for clinical text analysis to support changing the way modern medicine is practised.
I will discuss the formation and subsequent growth of IRDiRC into an organization with nearly 40 public and private funder members who have collectively pledged over 1 billion euros for rare disease research. I will also present the goals of IRDiRC, the plan that has been developed to achieve them, and the progress that has been made thus far. Finally, I will explore how additional organizations can take part in this international collaborative effort
The International AD Research Funder Consortium (IADRFC) aims to foster collaboration and data sharing between Alzheimer's disease research organizations through developing partnerships, standard templates, and influencing the international research agenda. The Global Alzheimer's Association Interactive Network (GAAIN) is a collaborative effort to provide researchers worldwide access to a vast repository of Alzheimer's research data by establishing a central data infrastructure and engaging data partners. GAAIN will transform heterogeneous local data into a common data model and terminology to allow integrated analysis across datasets.
Developing a national strategy to bring pathogen genomics into practiceExternalEvents
http://www.fao.org/about/meetings/wgs-on-food-safety-management/en/
Developing a national strategy to bring pathogen genomics into practice. Presentation from the Technical Meeting on the impact of Whole Genome Sequencing (WGS) on food safety management and GMI-9, 23-25 May 2016, Rome, Italy.
Healthcare Conference 2013 : Genes, Clouds and Cancer - dr. Andrew LittD3 Consutling
Dell Healthcare provides IT services to healthcare organizations worldwide. They serve over 50% of US hospitals, the top 10 pharmaceutical companies, and 100 insurance organizations. Dell Healthcare manages billions of medical images in the cloud, billions of security events daily, and provides genomic sequencing services. They are sponsoring the first FDA-approved clinical trial using whole genome sequencing to provide personalized cancer treatment to children with neuroblastoma. The trial aims to reduce analysis time from weeks to hours using Dell's high performance computing capabilities and improve collaboration using their genomics cloud. The goal is to expand personalized medicine from treating a few children to hundreds and thousands.
Investigating the Health of Adults: Leveraging Large Data Sets For Your Stud...CTSI at UCSF
Overview of UCSF-CTSI Comparative Effectiveness Large Dataset Analysis Core with emphasis on large, public data sets for studying the health of adults and the care they receive.
The workshop aimed to promote the development and use of atomically precise tools for medical applications. About 50 researchers from diverse fields attended to identify potential collaborations and near-term research projects. The workshop developed several example projects, such as using artificial immune systems or DNA robots to treat diseases. It also identified how precise tools could repair DNA, stem cells, or control blood composition to treat medical issues.
Welcome Remarks and Overview of CTSI ResourcesUCLA CTSI
Welcome Remarks and Overview of CTSI Resources
Steven Dubinett, MD
Director, UCLA Clinical and Translational Science Institute
President/CEO, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cell...QIAGEN
Would you like to measure signaling pathway activity in your favorite cell? Learn how to successfully apply convenient and robust reporter assays to your RNA interference, gene over-expression, protein, or small molecule studies. The Cignal Reporter Assays are an excellent tool for studying pathway signaling activity in cells that are amenable to transfection, available for studying numerous pathways including (ROS, Wnt, NF-kB, Notch, cAMP/PKA, TGFbeta, and the Cignal Lenti Reporter Assays combines the power of a lentiviral delivery system with our robust transcription factor reporter technology, enabling you to study signal pathways in virtually any cell type. You can find a technology overview, protocol tutorial, and application examples in the following presentation.
Biofluid miRNA profiling: from sample to biomarker: miRNA and its Role in Hum...QIAGEN
Circulating miRNAs have great potential as biomarkers due to their aberrant expression in cancer and other diseases. However, miRNAs from body fluids are hard to obtain in amounts sufficient for detailed miRNome profiling. This slideshow describes an integrated, PCR-based system that reduces the amount of sample required for full miRNome profiling by several orders of magnitude and provides unparalleled reproducibility and precision. Detailed protocols are highlighted regarding RNA isolation, real-time quantification and data analysis for the assessment of serum, plasma, urine and cerebrospinal fluid samples. This system enables accurate miRNA analysis on the smallest of samples and opens up new possibilities for biomarker development.
Functional Analysis of miRNA: miRNA and its Role in Human Disease Webinar Ser...QIAGEN
This slideshow highlights the use of miRNA mimics, inhibitors and target protectors to increase, decrease and adjust the cellular concentration of miRNA and disrupt specific miRNA–mRNA interactions. A ready-to-use screening tool for identifying miRNA targets and info on how to predict mRNA targets using miRNA expression data are also highlighted.
This document summarizes research on early detection of Alzheimer's disease using amyloid PET imaging. It defines dementia and Alzheimer's disease, and describes how amyloid plaques and neurofibrillary tangles are the characteristic brain pathology of Alzheimer's. Amyloid PET imaging allows visualization of amyloid plaques in the brain and has shown that amyloid accumulation is associated with future cognitive decline. Lifestyle factors like cognitive engagement may help reduce amyloid levels and dementia risk. The amyloid hypothesis proposes that amyloid accumulation leads to neural dysfunction, atrophy, and ultimately cognitive decline. Early detection of amyloid is important for research and clinical trials but not yet for routine clinical use.
Biomarker Diagnosis for Alzheimer's DiseaseThet Su Wynn
This document discusses biomarkers for the diagnosis of Alzheimer's disease. It defines biomarkers and describes their use to detect, stage, and monitor Alzheimer's. Biomarkers found in cerebrospinal fluid include decreased Aβ42 and increased total tau and phosphorylated tau. Genetic markers like mutations in APP, PSEN1 and PSEN2 can cause early-onset Alzheimer's. Circulating miRNAs show potential as non-invasive blood biomarkers. Mass spectrometry is used to analyze various protein biomarkers but none have been satisfactory for diagnosis. Reliable blood biomarkers are still being sought to allow early, fast and non-invasive Alzheimer's diagnosis.
- MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression through base pairing with messenger RNA (mRNA) molecules. They are encoded in the genome and are abundant in many human cell types.
- miRNAs play a vital role in genetic regulation and are involved in most biological processes. Aberrant miRNA expression has been implicated in many diseases.
- miRNAs are initially transcribed as long primary transcripts that are processed in the nucleus by the Drosha enzyme into hairpin-shaped precursor miRNAs. These are then exported into the cytoplasm and further processed by the Dicer enzyme into mature miRNAs that can regulate gene expression through pairing with mRNAs.
Mir193b–365 is essential for brown fat differentiation by regulating genes involved in adipogenesis. The study identified Mir193b-365 as a microRNA complex necessary for brown adipose tissue differentiation. Blocking Mir193b expression inhibited brown fat marker genes, pointing to its critical role in brown fat development. Mir193b-365 associates closely with mRNAs like Prdm16 and Pparα that help upregulate it during differentiation, inducing adipogenic factors while suppressing myogenic factors.
MicroRNAs (miRNAs) are small non-coding RNAs that play important gene regulatory roles in eukaryotic cells. They are approximately 22 nucleotides in length and are transcribed from independent genes or introns, then processed through a biogenesis pathway before targeting mRNAs for silencing or degradation. MiRNAs regulate genes involved in development, metabolism, and diseases like cancer. Their expression and function is tightly controlled through transcriptional and post-transcriptional mechanisms in order to influence protein expression levels. While much progress has been made in understanding miRNAs, further study is still needed to elucidate their complex regulatory networks and roles in development and disease.
Alzheimer's disease is a progressive brain disease that causes memory loss and cognitive decline. It is the most common cause of dementia among older adults. The disease is characterized by two hallmarks - neuritic plaques formed by amyloid-beta protein fragments, and neurofibrillary tangles made up of tau protein inside neurons. It gradually destroys brain cells in areas responsible for memory and cognition. While symptoms start out mild, the disease gets worse over time and can lead to severe brain damage. There are genetic and lifestyle risk factors associated with Alzheimer's but currently there is no cure.
This presentation was delivered to students at UC San Diego on May 2, 2012 by Dawn DeStefani, BSW, who is the director of programs and services for The Glenner Memory Care Centers in San Diego. Learn more at www.glenner.org.
Alzheimer's disease is a neurological disorder that causes memory loss and cognitive decline. It was first described by Dr. Alois Alzheimer in 1901 when examining patient Auguste D. The causes are not fully understood but involve genetic, environmental, and lifestyle factors. Early signs include memory problems and other cognitive declines. As it progresses, damage occurs in areas controlling language, reasoning, and thought, and patients have trouble recognizing family and friends. By the final stage, plaques and tangles have spread throughout the brain, causing severe impairment and dependence on others for care. While some drugs can temporarily stabilize symptoms, there is no cure for Alzheimer's disease.
Alzheimer's disease is a progressive degenerative disorder of the brain that initially involves memory loss and cognitive decline, and ultimately results in severe impairment in all areas of functioning. While medications can temporarily improve symptoms, there is no cure. The disease progresses through mild, moderate, and severe stages characterized by worsening memory loss, impaired communication and ability to care for oneself, and may eventually involve inability to walk or speak intelligibly. Patients and families require education and support to understand and cope with the progression of the disease.
Alzheimer's disease is the most common form of dementia. It is a neurodegenerative disease that causes deterioration of the brain and destruction of nerve cells. This leads to a loss of functioning in the brain and difficulties sending proper signals. While the cause is unknown, family history increases risk. Alzheimer's affects the brain, causing shrinkage and clumps/tangles that impair intellectual functioning. Symptoms worsen over 7 stages, from mild memory loss to severe impairment. Currently there is no cure, but drugs can help treat some symptoms.
Alzheimer's disease is a progressive neurodegenerative disease that causes loss of neurons and synapses in the brain. The main pathological hallmarks are extracellular amyloid beta plaques and intraneuronal neurofibrillary tangles. Current treatments only temporarily improve cognitive symptoms but do not stop progression of the disease. New treatments are needed to both maintain cognitive abilities and halt the underlying disease process.
Alzheimer's disease is a progressive brain disorder that causes memory loss and cognitive decline. It was first described by Alois Alzheimer in 1906 after examining brain tissue from a deceased patient. The disease results from the buildup of beta-amyloid plaques and tau protein tangles in the brain, which damage and kill neurons. Risk factors include age, family history, and genetic factors. There is no cure for Alzheimer's, but medications and caregiving can temporarily ease symptoms.
Alzheimer's disease is a progressive brain disorder that destroys memory and cognitive skills. Dr. Alois Alzheimer first described it in 1906 after examining a woman with dementia. The disease is characterized by beta-amyloid plaques and neurofibrillary tangles in the brain. Current treatments aim to improve symptoms but do not stop the underlying disease process. Researchers are exploring therapies targeting amyloid and tau proteins as well as other mechanisms to find a cure.
Alzheimer's disease is a progressive brain disorder that causes memory loss and cognitive decline. It is the most common form of dementia and develops due to a complex biological process in the brain over many years. Approximately 5.3 million Americans have Alzheimer's currently, and it is the fifth leading cause of death among those aged 65 and older. Symptoms include memory loss, problems with language, disorientation, and changes in mood and personality. Alzheimer's progresses through mild, moderate and severe stages as cognitive abilities and independence decline. While there is no cure, certain drugs can temporarily slow the worsening of symptoms for some individuals.
The document discusses the International Rare Disease Research Consortium (IRDiRC), which aims to deliver 200 new therapies and means to diagnose most rare diseases by 2020. It outlines IRDiRC's goals of international cooperation and data sharing between public and private funders. Over $1B has been committed worldwide by over 30 member organizations. Progress includes identifying genes for over 3,400 rare diseases and tests for over 3,300. 137 new therapies have been developed so far. Challenges include increasing gene discovery rates and establishing unified databases. Initiatives to address these include PhenoTips and Matchmaker Exchange for matching unsolved cases.
PRA Insights Report: Alzheimer's Disease ResearchEmma Whieldon
(1) The document summarizes the results of a survey conducted at the 2017 Alzheimer's Association International Conference to gather insights on Alzheimer's disease research. (2) Over half of respondents believed the foremost challenge in neuroscience drug development is target identification. (3) The amyloid hypothesis was seen as the most promising research area, though tau protein and inflammation were also viewed as important. (4) Pre-screening subjects in the community was believed to have the biggest positive impact on recruiting prodromal Alzheimer's patients.
The Uniform Data Set (UDS) is a longitudinal database maintained by the National Alzheimer's Coordinating Center (NACC) that collects standardized clinical data from 29 Alzheimer's Disease Centers (ADCs) across the US. The UDS aims to facilitate collaborative research among the ADCs by providing a large pool of standardized, high-quality data on Alzheimer's patients. It has supported over 500 publications and provides data to researchers studying Alzheimer's diagnosis, treatment, and causes. The NACC coordinates the ongoing development and usage of the UDS to advance Alzheimer's research.
Summary, outcomes and action plan presented by Dr. Angela Christiano at the end of the two-day Alopecia Areata Research Summit held November 14-15, 2016 in New York, NY.
This document describes the principles, organization, and operation of a DNA bank established by the Department of Veterans Affairs Cooperative Studies Program. The DNA bank was created to facilitate genetic research using DNA samples collected from participants in clinical trials and studies. Key aspects discussed include obtaining informed consent from participants, ensuring privacy and confidentiality, resolving issues around ownership and future use of genetic material, and providing an infrastructure to support linking genetic and clinical data. The DNA bank is intended to be a shared resource that can support future genetic research across multiple clinical studies in different disease areas over time.
This document outlines a public health approach for realizing the promises of genomics and big data while addressing the challenges. It recommends: 1) Using a strong epidemiological foundation to study disease distribution and determinants in populations. 2) Developing a robust knowledge integration process to synthesize findings from different sources and disciplines. 3) Applying principles of evidence-based medicine and population screening to evaluate genomic applications. 4) Developing a robust translational research agenda beyond clinical applications to improve population health impact. The public health framework can help maximize the benefits of genomics and big data while minimizing risks.
The document outlines various resources and programs available through the National Institutes of Health (NIH) to support research and development efforts, from early stage screening and validation to late stage clinical trials. It describes screening programs, technology characterization services, preclinical and clinical development resources across multiple NIH institutes focused on areas like cancer, neurodegeneration, infectious diseases, and more. The document encourages collaborations between NIH researchers and outside entities through licensing agreements, cooperative research agreements, and material transfers to help move technologies toward public health benefits.
Alzheimer's disease (AD) is recognized as a public health crisis worldwide (IADRP, 2013). AD is a complex neurodegenerative disease and the leading cause of dementia among the elderly people (Evans et al., 1989). Currently, there are approximately five million AD cases in the United States and about 35 million cases worldwide (Alzheimer's Disease International, 2009.
The focus of this case study is on the Uniform Data Set (UDS), a longitudinal database on Alzheimer’s patients, and the 29 Alzheimer’s Disease Centers (ADC) that submit their data to the UDS and actively collaborate in the ongoing maintenance, development and research utilization of the database. The ADCs are based in major medical institutions across the United States. They have a multi-decade track record of collaborative research and a networked and virtual approach to the scientific study of AD. The central coordinating mechanism for the ADCs and the UDS is the National Alzheimer’s Coordinating Center (NACC), which is located at the University of Washington. The NACC coordinates data collection and supports collaborative research among the ADCs.
The document discusses the intersection of precision medicine, biomarkers, and healthcare policy. It describes how biomarkers and -omics data can be used for precision medicine to improve diagnostic accuracy, deliver targeted therapies, and stratify patient populations. However, clinical validation of biomarkers now requires large datasets and years of studies due to regulatory and payer requirements. This has reduced incentives for diagnostic innovation. The document also discusses challenges around clinical interpretation of complex multi-omic tests, evolving medical training and workflows, and disconnects between patent and reimbursement policies.
This document presents an overview of the AI applications in life sciences. The presentation highlights various steps in drug development and AI applications. Also, discusses Alzheimer’s disease and obstacles to develop drugs. Finally, presents details of AI in target identification for AD.
This disclaimer informs readers know that the views, thoughts, and opinions expressed in the presentation belong solely to the author, and not to the author’s employer, organization, committee or other group or individual.
Genomic epidemiology uses whole genome sequencing data from pathogens combined with epidemiological investigations to track the spread of infectious diseases. The document discusses making genomic epidemiology a widespread reality in public health. It outlines key requirements including building a user-friendly analysis platform, developing portable analysis pipelines, providing training to public health personnel, and improving information sharing between organizations.
How Can We Make Genomic Epidemiology a Widespread Reality? - William HsiaoWilliam Hsiao
The document discusses genomic epidemiology and the requirements to bring genomic sequencing into routine public health practice. It outlines two parts: (1) what genomic epidemiology is and why it is important; and (2) the requirements for genomic sequencing to be used routinely in public health. Whole genome sequencing is seen as a way to generate high quality pathogen genomes quickly and allow for more detailed tracking of disease spread compared to traditional methods. However, bringing genomic sequencing into public health practice requires overcoming barriers such as the need for user-friendly analysis platforms, training public health personnel in genomics, and improving information sharing between organizations.
The document outlines Canada's Rare Disease Strategy, which aims to improve the lives of those affected by rare diseases through 5 key goals: 1) improving early detection and prevention, 2) providing timely, equitable care, 3) enhancing community support, 4) providing sustainable access to therapies, and 5) promoting innovative research. Rare diseases affect over 2.8 million Canadians and early detection is challenging, with many receiving misdiagnoses or facing long wait times. The strategy seeks to establish newborn screening, genetic testing guidelines, clinical expertise centers, and a national rare disease drug program to help ensure Canadians have consistent access to treatments.
This document summarizes a study that conducted a stocktake of New Zealand's healthcare datasets. It identified 286 datasets across various categories held by different custodian organizations. Most datasets belonged to the Ministry of Health, universities, and district health boards. About half of the datasets contained individually identifiable patient data. The study found that while data quality and access protocols varied, there is significant value in New Zealand's health data assets. However, barriers around privacy and appropriate use would need to be addressed to fully realize this value. The study recommends making the stocktake information more accessible online and continuing to explore opportunities and address challenges around secondary use of the data.
2016 Data Commons and Data Science Workshop June 7th and June 8th 2016. Genomic Data Commons, FAIR, NCI and making data more findable, publicly accessible, interoperable (machine readable), reusable and support recognition and attribution
This document provides an overview of the November 2000 issue of JALA (Journal of Analytical Laboratories Automation). It describes the development of a novel robotic system for the New York Cancer Project biorepository in collaboration with the Medical Automation Research Center. The biorepository receives 50-100 blood samples per day which are processed robotically to extract, quantify, aliquot and store DNA, plasma and RNA to be accessible to investigators. The robotic system aims to provide rapid random access to the hundreds of thousands of DNA samples stored for high-throughput analysis in studies of gene-environment interactions and cancer risk.
Nicholas Black: Linking disease registry information Nuffield Trust
This document discusses linking disease registry information and predictive modeling. It describes the characteristics of national clinical databases in England, including three main types: routine administrative databases, clinical registries, and national clinical audits. Over 60 national clinical audits exist, covering a wide range of clinical areas. The document advocates expanding the use of national clinical databases to support decision-making and predictive modeling.
Similar to Global Dementia Legacy Event: Dr Neil Buckholtz (20)
No voice unheard, no right ignored: consultation for people with learning dis...Department of Health
The document outlines proposals to strengthen the rights of people with mental health needs, learning disabilities, and autism in the UK. It discusses 5 key areas for reform: 1) the right to independent living and community inclusion, 2) the right to have one's wishes heard and decisions challenged, 3) rights under the Mental Health Act, 4) the right to control one's own support through personal budgets, and 5) improved coordination between health and social services. The consultation seeks public input on these proposals to ensure laws and policies fully respect the rights of those with mental health conditions or disabilities.
Creating digital tools for mental health and employment support: the discover...Department of Health
This report maps out the needs of potential users of an online mental health and work assessment and support service, suggests key user groups and presents a set of design principles for any a potential future service.
Creating digital tools for mental wellbeing and employment support: pre-alpha...Department of Health
This slide-deck reports on the second phase user research and testing. It presents refined design briefs that can be used to inform future alpha stages and design of a future service. These are themed according to the three core user groups identified in the first phase:
(i) finding work
(ii) in and out of work
(iii) managing work.
Further information on:
- user testing details
- mock-ups of potential digital tools for people finding work
- mock-ups of potential digital tools for people moving in and out of work
- mock-ups of potential digital tools for people managing work
Global Dementia Legacy Event: Canada & France: Dr Etienne Hirsch & Dr Yves Jo...Department of Health
Session Five: The next goal – towards Canada, France, Japan and the United States.
Canada & France: Dr Etienne Hirsch, Director, Institute for Neurosciences, Cognitive sciences, Neurology and Psychiatry at INSERM and the French alliance for life and health science Aviesan & Dr Yves Joanette CIHR, Scientific Director, Canadian Institutes of Health Research (CIHR), Institute of Aging & World Dementia Council Member
Feature presentation - The economic case for action
Professor Martin Knapp, Director, Health &
Personal Social Services Research Unit, London School of Economics & Kings College London
Session Four: Exploring the financial mechanisms that can be harnessed to increase investment in
dementia.
Professor Andrew Lo, MIT Sloan Professor of Finance
Session Four: Exploring the financial mechanisms that can be harnessed to increase investment in
dementia.
Mr. George Vradenburg, Convenor, The Global CEO Initiative on Alzheimer's and Chairman of USAgainstAlzheimer’s & World Dementia Council Member
Marc Wortman, Executive Director, Alzheimer’s Disease International (ADI) Department of Health
Session Three: To explore ways in which we can increase investment in innovation. Part 2 presents a case study of innovation across the globe and the need to continue global collaboration
Marc Wortman, Executive Director, Alzheimer’s Disease International (ADI)
Session Three: To explore ways in which we can increase investment in innovation. Part 2 presents a case study of innovation across the globe and the need to continue global collaboration
DY Suharya, Executive Director of Alzheimer's Indonesia
Session 3: To explore ways in which we can increase investment in innovation. In part 1 panellists will highlight ways in which they are seeking to tackle barriers and find solutions, including through big data, patient involvement in clinical trials and social investment.
Mr. Stephen Johnston, Co-Founder, Aging2.0 & Partner, Generator Ventures
Session 3: To explore ways in which we can increase investment in innovation. In part 1 panellists will highlight ways in which they are seeking to tackle barriers and find solutions, including through big data, patient involvement in clinical trials and social investment.
Mr. Tom Wright CBE, Group CEO, Age UK
Global Dementia Legacy Event: Ms Inez Jabalpurwala, President and CEO, Brain ...Department of Health
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia
Ms Inez Jabalpurwala, President and CEO, Brain Canada Foundation
Global Dementia Legacy Event: Raj Long, Senior Regulatory OfficerDepartment of Health
Raj Long presented on regulatory challenges for dementia treatment development and proposed innovative regulatory approaches. Key challenges included the prolonged time required for R&D, uncertainties around classifying and measuring dementia, and regulatory variances between geographies. These factors increase costs and risks for pharmaceutical companies, deterring investment. To address this, Long suggested regulatory designations to expedite review, adaptive development and licensing models, increased international regulator collaboration, incentives for developers, and public-private partnerships to accelerate cure discovery by 2025. Current approaches were deemed insufficient given the high risks and costs of dementia R&D.
The document discusses the need for global collaboration to conquer Alzheimer's disease. It notes that knowing is not enough and we must apply what we know. It advocates changing the dialogue around Alzheimer's to focus on the disease rather than just the patient. Key needs for "disease interception" are identified, including increased investment in basic science, incentivizing innovators, improving diagnostic tools and biomarkers, establishing clinical trial registries, building translational infrastructure between registries and trial-ready cohorts, using relevant outcomes measures, and creating a synchronized regulatory environment. The presentation promotes the Global Alzheimer's Platform as a way to foster data sharing, collaboration, and building a "global connectome" to accelerate progress on Alzheimer's.
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.
Elisabetta Vaudano DVM PhD, Coordinator Scientific Pillar, Principal Scientific Manager, Innovative Medicines Initiative
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.
John Ryan, Acting Director of the European Commission Public Health Directorate
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.
Professor Lefkos Middleton, Professor of Neurology, Neuroepidemiology and Ageing Research at School of Public Health, Imperial College London
Dr Shekhar Saxena, Director of the Department of Mental Health and Substance Abuse at World Health Organization (WHO) & Technical Advisor to the World Dementia Council
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)MuskanShingari
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
2. International Alzheimer’s Disease Research
Portfolio (IADRP)
• Developed by NIA in collaboration with Alzheimer’s Association.
• Will enable funders of Alzheimer’s research to coordinate
planning, leverage resources, avoid duplication, and identify
new opportunities.
• Will give the public a full picture of the scale of ongoing research
on AD both nationally and internationally.
http://iadrp.nia.nih.gov/cadro-web/
3. CADRO is a three-tier classification system created by NIA and the Alzheimer’s Association to capture
the complete range of AD research
First level of classification consists of seven categories: 5 research and 2 research resources-related:
Category A – Molecular Pathogenesis and Physiology of Alzheimer’s Disease
Category B – Diagnosis, Assessment and Disease Monitoring
Category C – Translational Research and Clinical Interventions
Category D – Epidemiology
Category E – Care, Support and Health Economics of Alzheimer’s Disease
Category F – Resources for the Research Community
Category G – Consortia and Public Private Partnerships
Each category is divided into “research topics”; many topics further divided into “research themes”
Detailed classification will enable funders and researchers to identify research gaps, areas of
overlap/duplication of effort, and opportunities for collaboration with much greater specificity
http://www.nia.nih.gov/research/dn/international-alzheimers-disease-research-portfolio
Common Alzheimer’s Disease Research Ontology
(CADRO) Structure
4. Web-based portal developed by NIA and the Alzheimer’s Association:
Alzheimer’s and related dementias research funded projects 2008 to 2012.
Currently includes: Federal agencies (including NIH, AHRQ, CDC, AoA, VA and
DoD), Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, and
Alzheimer’s Research UK, Alzheimer’s Society UK, Alzheimer’s Society of
Canada, and Alzheimer’s Australia.
Summer 2014: Additional funders (10) and 2013 data will be available on IADRP.
http://iadrp.nia.nih.gov/cadro-web/
5. 1. Amyloid
32%
2. Tau
6%
3. Presenilins
4%
4. ApoE and Lipids
9%
5. Brain
Circuits and
Synapses
7%
6. Neurogenesis Cell
Death
5%
7. Immunity and
Inflammation
10%
8. Bioenergetics
1%
9. Vascular/Metabolic
Factors
5%
10. Hormones
3%
11. Genetics
11%
12. Other Pathogenic
Mechanisms
7%
Proportion of ‘Category A’ Projects by Topic across All
Funding Organizations (2012)
6. 20%
30%
40%
50%
60%
70%
80%
90%
100%
2008 2009 2010 2011 2012
12. Other Pathogenic Mechanisms
11. Genetics
10. Hormones
9. Vascular/Metabolic Factors
8. Bioenergetics
7. Immunity and Inflammation
6. Neurogenesis Cell Death
5. Brain Circuits and Synapses
4. ApoE and Lipids
3. Presenilins
2. Tau
1. Amyloid
Changes in the Proportion of ‘Category A’ Projects by Topic
for All Funding Organizations (2008 - 2012)
7. Step 1
Funding organizations identify
their respective AD and AD-
related dementia projects
Step 2
Funding organizations provide
the IADRP Team with projects
in a designated excel template
or via links to projects online
along with specified data
elements and abstracts
Step 3
The IADRP Team codes
projects (via an automated
coding portal) using the
Common Alzheimer's Disease
Research Ontology (CADRO)
(http://www.nia.nih.gov/resea
rch/dn/cadro-outline)
Step 4
Funding organizations validate
the coding via the coding
portal
Step 5
Coded and validated projects
are uploaded into the IADRP
online database
(http://iadrp.nia.nih.gov)
Portfolio Analysis
All users can systematically
compare and analyze funding,
composition of research,
specific trends in funding over
time, geographic distribution
of projects, and overlapping
funding priorities
IADRP Submission Process
12. AMP Project A
• Supplement the imaging and fluid biomarker panels
already included in these three NIH-funded Phase II/III
registration trials in presymptomatic Alzheimer’s through
the addition of tau PET imaging, EEG measures, and
novel fluid biomarkers.
14. AMP Project B
• Apply integrated network analyses (RNA, proteomic,
other “omic” studies) in 2500 human AD brain samples to
identify biologic nodes and networks that are linked to
the development or progression of AD to identify new
targets for drug development.
• Create standardized open-source data structures and
formats to aid the accessibility and ease of analysis of
biological data in a manner not currently practiced in the
AD field.
15. Pathway discovery, validation and compound identification for Alzheimer's disease*
Phil De Jager (Contact PI) Broad Institute
David Bennett Rush University
Integrative Biology Approach to Complexity of Alzheimer's Disease*
Eric Schadt (Contact PI) Icahn Institute for Multiscale Biology at Mount Sinai & Dept of
Genetics and Genomics Sciences
A System Approach to Targeting Innate Immunity in AD*
Todd Golde (Contact PI) – University of Florida
Nathan Price – Institute for Systems Biology, Seattle
Nulifer Ertiken-Taner and Steven Younkin – Mayo Clinic Jacksonville
Funded Projects
Allan Levey (Contact PI) Emory University
Discovery of Novel Proteomic Targets for Treatment of Alzheimer's Disease*
Lara Mangravite and Stephen Friend –Sage Bionetworks
Administrative Supplements for Data Enablement and Data Integration